Highnoon Labs

What Highnoon Labs does

Highnoon Laboratories Limited is a Pakistan-based pharmaceutical manufacturer and distributor founded in 1984 and headquartered at Multan Road, Lahore. The company was incorporated as a Private Limited Company in March 1984, became a Public Limited Company in 1995, and is listed on all Pakistan stock exchanges under the ticker HINOON. Its core business is the formulation, manufacturing, and marketing of branded generic and specialty pharmaceutical products, with a portfolio of more than 50 products spanning 10 therapeutic categories: Cardiology, Metabolic, Gastroenterology, Musculoskeletal, Anti-infective, Obstetrics and Gynaecology, Paediatrics, Allergy, Respiratory, and Urology.

Highnoon manufactures at a cGMP-compliant facility in Lahore (ISO 9001 certified since 1998) and draws its product portfolio from a long-running set of technology alliances with global pharmaceutical research houses, including Chugai Pharma and Mitsubishi Tanabe (Japan), Almirall Prodesfarma (Spain), Solvay Pharmaceuticals (Germany), Cipla (India), Acino Pharma (Switzerland), and others. The company holds a UK patent for a novel oral rehydration formulation called Peptilose, and its respiratory product line (Combivair, Tiovair, Minvair, Ultivair) is built on the Cipla partnership introduced in 2009. It has earned four consecutive Forbes Asia 'Best Under a Billion' recognitions (2019, 2021, 2022, 2023), a Best Performance Award from the President of Pakistan in 2012, and was reported by IQVIA as achieving PKR 10 billion in sales in 2020.

The commercial model is sales-led: a nationwide field force of medical representatives markets directly to doctors, hospitals, and pharmacies across both private and public sectors in Pakistan, supplemented by export operations to Vietnam and Sri Lanka (since 2009) and a contract manufacturing business producing for international partners under licensing agreements. The company targets therapeutic-area prescribers as its primary customer segment, with secondary revenue from public-sector hospital procurement and international partners. Headcount stands at more than 1,000 employees nationwide, and Highnoon describes itself as the first Pakistan-origin pharmaceutical company to enter the top twenty league of the domestic pharmaceutical industry. ESG initiatives include long-running free-medicine donations to thalassemia patients via four Pakistani welfare foundations and rural free medical camps.

Name

Highnoon Labs

Legal name

Highnoon Laboratories Limited

Website

https://highnoon-labs.com

Company type

Public

Founded year

1984

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Highnoon Laboratories Limited is a Pakistan-based, publicly listed pharmaceutical manufacturer (PSX: HINOON) with 1,000+ employees and a portfolio of 50+ branded products across 10 therapeutic categories, sold through a nationwide sales force domestically and direct marketing operations in Vietnam and Sri Lanka.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Specialty Care Pharmaceuticals (HLAIAAAB), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Respiratory & Allergy Pharmaceuticals (HLAIAAAH)

Keywords

• Pharmaceutical manufacturing
• Branded generic medicines
• Contract manufacturing services
• Cardiovascular medications
• Anti-infective drugs

Headquarters

HQ city

Lahore

HQ country

Pakistan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Sale of proprietary pharmaceutical products across 10 therapeutic categories including Cardiology, Metabolic, Gastroenterology, Musculoskeletal, Anti-infective, Obstetrics and Gynaecology, Paediatrics, Allergy, Respiratory, and Urology
2. Export Sales: International exports to markets including Vietnam and Sri Lanka
3. Contract Manufacturing: Manufacturing products for international pharmaceutical partners under licensing agreements

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Highnoon Laboratories manufactures and markets proprietary pharmaceutical formulations across 10 therapeutic categories including Cardiology, Metabolic, Gastroenterology, Musculoskeletal, Anti-infective, Obstetrics and Gynaecology, Paediatrics, Allergy, Respiratory, and Urology. The company operates cGMP-compliant manufacturing facilities in Lahore and distributes through a nationwide sales force targeting healthcare professionals in Pakistan, with international exports to Vietnam and Sri Lanka and contract manufacturing services for global pharmaceutical partners.

Product overview

Highnoon Laboratories Limited is a Pakistani pharmaceutical company offering a diverse portfolio of more than 50 products across 10 therapeutic categories: Cardiology, Metabolic, Gastroenterology, Musculoskeletal, Anti-infective, Obstetrics and Gynaecology, Paediatrics, Allergy, Respiratory, and Urology. The product portfolio includes cardiovascular medications (antihypertensives, anticoagulants, statins), metabolic treatments (diabetes medications including DPP-4 inhibitors, SGLT2 inhibitors, combination therapies), anti-infectives (antibiotics, antivirals, antimalarials), gastroenterology products (PPIs, hepatology treatments), respiratory medications (inhalers, bronchodilators, corticosteroids), musculoskeletal treatments (NSAIDs, analgesics, gout medications), and other therapeutic areas. The company operates manufacturing facilities compliant with cGMP standards and focuses on both national and international markets.

Differentiator

Problem solved

Functional benefit

Products and services

• Cardiology Product Portfolio Cardiovascular medications including antihypertensives (Nebix/Nebivolol, Cuziper/Bisoprolol, Misar/Telmisartan, Blokium/Atenolol, Ivaset/Ivabradine), anticoagulants (Pidogrel/Clopidogrel, Hitica/Ticagrelor, Apiban/Apixaban, Rivaro/Rivaroxaban), statins (Lipirex/Atorvastatin, Rosulin/Rosuvastatin), antiplatelet (Loprin/Aspirin), heart failure treatments (Sacuvia, Epliron, Triforge, Biforge), and antianginal (Ranola/Ranolazine).
• Metabolic Product Portfolio Metabolic medications primarily for Type 2 Diabetes Mellitus including DPP-4 inhibitors (Vylinta/Linagliptin, Tagip/Sitagliptin), SGLT2 inhibitors (Daploz/Dapagliflozin, Diajard/Empagliflozin) and their combination products with Metformin, and other metabolic treatments (Fildil/Tadalafil, Moblo/Mecobalamin, Dlexet/Duloxetine).
• Gastroenterology Product Portfolio Gastroenterology medications including proton pump inhibitors (Omevex/Omeprazole, Rabecid/Rabeprazole, Axesom/Esomeprazole, Inhibitol/Lansoprazole, DXL/Dexlansoprazole), antiemetics (Emesson/Ondansetron), hepatology products for Hepatitis C (Fosbu/Sofosbuvir, Fosbu V, Daclata/Daclatasvir), gastrointestinal motility agents (Cidine/Cinitapride, Racedo/Racecadotril), bowel preparations (Skilax), and antiulcerants (Ulsanic/Sucralfate).
• Musculoskeletal Product Portfolio Musculoskeletal medications including NSAIDs (Hinocam/Piroxicam, Airtal/Aceclofenac), analgesics (Kydor/Ketorolac, Tamadol/Tramadol, Seden-P/Tramadol+Paracetamol), neuropathic pain treatments (Hilin/Pregabalin), and gout medication (Hiloric/Febuxostat).
• Anti-infective Product Portfolio Anti-infective medications including cephalosporin antibiotics (Ceflaro/Ceftaroline, Bactiplan/Teicoplanin, Venjar/Vancomycin, Merzel/Meropenem, Evacef/Cefadroxil, Maxum/Cefepime, Fortez/Ceftazidime, Xorbact/Sulbactam-Cefoperazone, Cefia/Cefixime, Ceftro/Ceftriaxone, Efix/Cefixime), fluoroquinolones (Cyrocin/Ciprofloxacin, Voxiquin/Levofloxacin, Oxaquin/Moxifloxacin), macrolides (Azipos/Azithromycin), and antimalarials (Artecxin/Artemether-Lumefantrine).
• Obstetrics and Gynaecology Product Portfolio Obstetrics and Gynaecology medications including aromatase inhibitors (Hitase/Letrozole) for adjuvant treatment of postmenopausal women with early breast cancer.
• Paediatrics Product Portfolio Paediatric medications including appetite stimulants (Tres Orix Forte/Cyproheptadine Orotate syrup) for anorexia in children and adults.
• Allergy Product Portfolio Allergy medications including antihistamines (Leviva/Levocetirizine, Kestine/Ebastine) for allergic rhinitis and chronic urticaria.
• Respiratory Product Portfolio Respiratory medications including dry powder inhalers and combinations (Minvair, Ultivair-M, Glynvair, Betatec, Ultivair, Combivair Forte, Tiovair-F, Combivair, Tiovair, Breavent), inhaler devices (Powerhaler, Rotaflo, Revolizer), anti-inflammatory respiratory treatment (Pirfenox/Pirfenidone for idiopathic pulmonary fibrosis), and leukotriene receptor antagonists (Montit/Montelukast).
• Urology Product Portfolio Urology medications including alpha-blockers (Prostam/Tamsulosin HCI) for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).
• Contract Manufacturing Services Contract manufacturing services for international pharmaceutical partners under licensing agreements, utilizing cGMP-compliant manufacturing facilities in Lahore.
• Feripro (Deferiprone) Donation Program Free distribution of Feripro (Deferiprone) iron-chelating capsules to thalassemia patients through partnerships with multiple Thalassemia societies including Thalassemia Society, Fatimid Foundation, Sundus Foundation, and Help International Welfare Trust of Pakistan.

Quantifiable outcome

• First pharmaceutical company of Pakistan origin to be in top twenty league of Pakistan pharmaceutical industry

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Six partnerships are on record, tiered core.

• Acino Pharma, SwitzerlandcoreTechnology or Integration · 1 January 2011Agreement signed in 2011 for Oncology products partnership.
• Cipla, IndiacoreTechnology or Integration · 1 January 2009Business partnership agreement signed in 2009. Launched respiratory products including Combivair (Budesonide + Formoterol Fumarate) dry powder inhaler, Tiovair (Tiotropium), and Tiovair F (Tiotropium + Formoterol).
• Almirall Prodesfarma, SpaincoreTechnology or Integration · 1 January 2001Obtained manufacturing and marketing rights of novel antihistamine Kestine (Ebastine) in 2001. Acquired brand Tres Orix Forte for Pakistan and Kenya in 2004. Painkiller drug Airtal (Aceclofenac) launched in 2006.
• Solvay Pharmaceuticals, GermanycoreTechnology or Integration · 1 January 1993Local manufacturing of Solvay Pharmaceuticals products started in 1993.
• Mitsubishi Tanabe, JapancoreTechnology or Integration · 1 January 1986Launched antihypertensive drug Herbesser (Diltiazem) tablet in 1986. Later partnership for ACE inhibitor Tanatril (Imidapril) 10mg tablets launched in 1996.
• Chugai Pharma, JapancoreTechnology or Integration · 1 January 1985Strategic alliance for manufacturing and marketing of Ulsanic (Sucralfate) 500mg tablet launched in 1985, representing Highnoon's first brand. Later expanded to include Ulsanic suspension in 2004.

Scale indicators7 records

Recent moves11 records

Expansion highlights6 records

Direct peers

• The Searle Company: Listed Pakistani pharma company with a diversified branded generics and specialty portfolio; competes directly with Highnoon in cardiology, metabolic and gastrointestinal categories in the domestic market.
• Getz Pharma: Pakistan-headquartered multinational pharmaceutical manufacturer with a broad multi-therapeutic portfolio (cardio, diabetes, respiratory, anti-infectives), competing head-to-head with Highnoon across the same prescription-driven GTM model.
• Bosch Pharmaceuticals: Karachi-based Pakistani pharma manufacturer with a broad therapeutic portfolio, competing with Highnoon in primary care and specialty categories domestically.
• Hilton Pharma: Karachi-based Pakistani pharma company with a broad portfolio across anti-infectives, cardiology and respiratory; competes with Highnoon for the same prescription and institutional channels.
• Sami Pharmaceuticals: Pakistani pharma manufacturer with multi-therapeutic branded generics, including respiratory and cardiology; comparable to Highnoon in domestic-focused sales-led model.
• AGP Limited: One of Pakistan's largest pharma manufacturers by volume, with a broad branded generics portfolio in cardiology, gastroenterology and anti-infectives; closely comparable to Highnoon in therapeutic mix and channels.
• Ferozsons Laboratories: Listed Pakistani pharma with branded generics and a hepatitis franchise; comparable to Highnoon in Pakistan-domiciled multi-therapeutic manufacturer profile and public-market governance.

Others

• Cipla: Indian multinational pharma partner of Highnoon (respiratory in-licensing since 2009); a relevant comparable as an emerging-market pharma exporter with a strong respiratory and branded generics portfolio.

Broad incumbents

• Abbott Laboratories (Pakistan): Multinational pharma incumbent in Pakistan offering a broad branded specialty and primary-care portfolio; overlaps with Highnoon in cardiology, metabolic, respiratory and gastroenterology.
• GlaxoSmithKline (Pakistan): Multinational pharma incumbent in Pakistan with a wide prescription and consumer health portfolio; competes with Highnoon in respiratory, vaccines, antibiotics and gastroenterology.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/highnoonlabs
• YouTubeyoutube.com/channel/UCX3bGCLbJ7lI5y
• Facebookfacebook.com/Highnoon-Laboratories-Limited-107468504732684
• LinkedInlinkedin.com/company/highnoon-laboratories-limited
• Instagraminstagram.com/highnoonpk

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Highnoon Labs